Canakinumab 150 mg Tied to Reduced Rate of Cardiac Events

This article originally appeared here.
Share this content:
Canakinumab 150 mg Tied to Reduced Rate of Cardiac Events
Canakinumab 150 mg Tied to Reduced Rate of Cardiac Events

MONDAY, Aug. 28, 2017 (HealthDay News) -- Canakinumab at a dose of 150 mg every three months is associated with reduced rate of cardiovascular events among patients with previous myocardial infarction, according to a study published online Aug. 27 in the New England Journal of Medicine. The research was published to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain.

Paul M. Ridker, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a randomized trial of canakinumab (50, 150, and 300 mg) involving 10,061 patients with previous myocardial infarction and high-sensitivity C-reactive protein level of ≥2 mg/L.

The researchers found that the median reduction from baseline in the high-sensitivity C-reactive protein level was 26, 37, and 41 percentage points greater in the groups that received 50, 150, and 300 mg of canakinumab, respectively, compared with the placebo group at 48 months. There was no reduction in lipid levels from baseline with canakinumab. The incidence rate for the primary end point (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) at a median follow-up of 3.7 years was 4.50, 4.11, 3.86, and 3.90 events per 100 person-years in the placebo group and the 50-, 150-, and 300-mg groups, respectively. The 150-mg dose met the prespecified threshold for significance for the primary end point and secondary end point (hazard ratio versus placebo, 0.83).

"Canakinumab at a dose of 150 mg every three months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Novartis, which manufactures canakinumab and funded the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Structural Findings of Acute Solar Retinopathy Described

Structural Findings of Acute Solar Retinopathy Described

Patient in case study presented three days after viewing solar eclipse

Telomere Fusions Predict Dysplasia, Invasive Pancreatic CA

Telomere Fusions Predict Dysplasia, Invasive Pancreatic CA

Telomere fusions are detected in later stages of intraductal papillary mucinous neoplasm progression

Prenatal Sugar Intake May Increase Asthma Risk in Offspring

Prenatal Sugar Intake May Increase Asthma Risk in ...

Higher intake during pregnancy, in early childhood associated with childhood asthma development

is free, fast, and customized just for you!

Already a member?

Sign In Now »